Carboplatin
Ovarian Clear Cell Adenocarcinoma
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
NRG Oncology
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02713386CT.gov Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT02446600CT.gov Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Active Not Recruiting | — | — | — |
NCT00989651CT.gov Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Clear Cell Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | NRG Oncology | P3 | BBB · 72 |
| Olaparib | National Cancer Institute (NCI) | P3 | BB |
| Adriamycin | National Cancer Institute (NCI) | P3 | BB |
| Cediranib | National Cancer Institute (NCI) | P3 | BB |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P2 | B |
| Nogitecan | National Cancer Institute (NCI) | P2/3 | B |
| Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine | Mayo Clinic | P2 | B |
+33 more in the Ovarian Clear Cell Adenocarcinoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Carboplatin in Ovarian Clear Cell Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/carboplatin-ovarian-clear-cell-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →